Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins

BackgroundCancer cell resistance to therapeutics can result from acquired or de novo-mediated factors. Here, we have utilised advanced breast cancer cell culture models to elucidate de novo doxorubicin resistance mechanisms.MethodsThe response of breast cancer cell lines (MCF-7 and MDA-MB-231) to doxorubicin was examined in an in vitro three-dimensional (3D) cell culture model. Cells were cultured with Matrigel™ enabling cellular arrangements into a 3D architecture in conjunction with cell-to-extracellular matrix (ECM) contact.ResultsBreast cancer cells cultured in a 3D ECM-based model demonstrated altered sensitivity to doxorubicin, when compared to those grown in corresponding two-dimensional (2D) monolayer culture conditions. Investigations into the factors triggering the observed doxorubicin resistance revealed that cell-to-ECM interactions played a pivotal role. This finding correlated with the up-regulation of pro-survival proteins in 3D ECM-containing cell culture conditions following exposure to doxorubicin. Inhibition of integrin signalling in combination with doxorubicin significantly reduced breast cancer cell viability. Furthermore, breast cancer cells grown in a 3D ECM-based model demonstrated a significantly reduced proliferation rate in comparison to cells cultured in 2D conditions.ConclusionCollectively, these novel findings reveal resistance mechanisms which may contribute to reduced doxorubicin sensitivity.

[1]  L. Kunz-Schughart,et al.  Multicellular tumor spheroids: an underestimated tool is catching up again. , 2010, Journal of biotechnology.

[2]  Kristiina Vuori,et al.  Integrin Signaling in Cancer Cell Survival and Chemoresistance , 2012, Chemotherapy research and practice.

[3]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[4]  Joe W Gray,et al.  Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. , 2006, Cancer research.

[5]  Andreas Krieg,et al.  Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines , 2013, PloS one.

[6]  S. Hilsenbeck,et al.  β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib , 2011, Breast Cancer Research.

[7]  L. Solin,et al.  Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment. , 2013, Clinical breast cancer.

[8]  K. Borden,et al.  Mechanisms and insights into drug resistance in cancer , 2013, Front. Pharmacol..

[9]  N. Cordes,et al.  Focal adhesion signaling and therapy resistance in cancer. , 2015, Seminars in cancer biology.

[10]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[11]  A. González-Angulo,et al.  Adjuvant systemic therapies in breast cancer. , 2013, The Surgical clinics of North America.

[12]  Vicky M. Avery,et al.  Evaluation of chemotherapeutics in a three-dimensional breast cancer model , 2015, Journal of Cancer Research and Clinical Oncology.

[13]  Robert A. Gatenby,et al.  Environment-mediated drug resistance: a major contributor to minimal residual disease , 2009, Nature Reviews Cancer.

[14]  J. Uhm,et al.  Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  K. Tsuchida,et al.  Tumor-Stroma Interaction of Human Pancreatic Cancer: Acquired Resistance to Anticancer Drugs and Proliferation Regulation Is Dependent on Extracellular Matrix Proteins , 2004, Pancreas.

[16]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[17]  S. Takayama,et al.  Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[18]  M. Rebucci,et al.  Molecular aspects of cancer cell resistance to chemotherapy. , 2013, Biochemical pharmacology.

[19]  H. Yoon,et al.  Aspirin-induced Bcl-2 translocation and its phosphorylation in the nucleus trigger apoptosis in breast cancer cells , 2013, Experimental & Molecular Medicine.

[20]  Bone-stromal cells up-regulate tumourigenic markers in a tumour-stromal 3D model of prostate cancer , 2013, Molecular Cancer.

[21]  Joachim P. Spatz,et al.  In vitro cancer cell-ECM interactions inform in vivo cancer treatment. , 2016, Advanced drug delivery reviews.

[22]  Vicky M. Avery,et al.  Advanced Cell Culture Techniques for Cancer Drug Discovery , 2014, Biology.

[23]  Mina J Bissell,et al.  Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. , 2008, Cancer research.

[24]  I. Tannock,et al.  The Tumor Microenvironment and Strategies to Improve Drug Distribution , 2013, Front. Oncol..

[25]  R. Legare,et al.  Adjuvant therapy in breast cancer. , 2002, Obstetrics and gynecology clinics of North America.

[26]  Joe W. Gray,et al.  HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment , 2010, Breast Cancer Research and Treatment.

[27]  F. Sigaux,et al.  α2β1 Integrin Promotes Chemoresistance against Doxorubicin in Cancer Cells through Extracellular Signal-regulated Kinase (ERK)* , 2012, The Journal of Biological Chemistry.

[28]  F. Aoudjit,et al.  Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells , 2001, Oncogene.

[29]  Shuichi Takayama,et al.  High-throughput 3D spheroid culture and drug testing using a 384 hanging drop array. , 2011, The Analyst.

[30]  Muhammad Zaman,et al.  Alteration of Cellular Behavior and Response to PI3K Pathway Inhibition by Culture in 3D Collagen Gels , 2012, PloS one.

[31]  D. Noonan,et al.  The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp‐9) activity , 2000 .

[32]  Crispin R Dass,et al.  Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems , 2013, The Journal of pharmacy and pharmacology.

[33]  G. Taglialatela,et al.  Bcl-2 Localized at the Nuclear Compartment Induces Apoptosis after Transient Overexpression* , 2006, Journal of Biological Chemistry.

[34]  C. Lovitt,et al.  Miniaturized three-dimensional cancer model for drug evaluation. , 2013, Assay and drug development technologies.

[35]  J. Dittmer,et al.  The impact of tumor stroma on drug response in breast cancer. , 2015, Seminars in cancer biology.

[36]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[37]  A. Chambers,et al.  β1-Integrin: A Potential Therapeutic Target in the Battle against Cancer Recurrence , 2011, Clinical Cancer Research.